19:00 , Dec 7, 2018 |  BC Week In Review  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported...
01:15 , Dec 7, 2018 |  BC Extra  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported significantly...
23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Propagermanium and irbesartan: Interim Phase II data

Interim data from 11 CKD patients with proteinuria who completed the 90 mg dose level in the dose-escalation part A of an open-label, Australian Phase II trial showed DMX-200 led to about a >=50% reduction...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Sparsentan: Phase II data

Top-line combined data from the 3 sparsentan cohorts in the double-blind, international Phase II DUET trial in 96 evaluable patients with focal segmental glomerulosclerosis showed that once-daily oral sparsentan met the primary endpoint of reducing...
07:00 , Sep 7, 2016 |  BC Extra  |  Clinical News

Retrophin jumps on Phase II FSGS data

Retrophin Inc. (NASDAQ:RTRX) rose $4.49 (28%) to $20.81 on Wednesday after it said combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021 ) met the trial's primary endpoint...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Sparsentan: Completed Phase II enrollment

Retrophin completed enrollment of >100 patients in the double-blind, international Phase II DUET trial comparing 200, 400 and 800 mg oral RE-021 once daily for 8 weeks vs. once-daily oral irbesartan. Patients are eligible to...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Propagermanium and irbesartan: Phase II started

Sun began an open-label, Australian Phase II trial of thrice-daily oral propagermanium in up to 60 patients receiving stable irbesartan. The first part of the trial will enroll up to 30 patients and evaluate escalating...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Shionogi sales and marketing update

Shionogi launched once-daily, oral Irtra irbesartan/trichloromethiazide in Japan to treat hypertension. The low dose tablet contains 100 mg irbesartan and 1 mg trichloromethiazide and the high dose tablet contains 200 mg irbesartan and 1 mg...